WINT Stock - Windtree Therapeutics, Inc.
Unlock GoAI Insights for WINT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-84,000 | $-82,000 | $-1,061,000 | $-869,000 | $-638,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-25,019,000 | $-17,539,000 | $-41,333,000 | $-77,280,000 | $-30,317,000 |
| Net Income | $-5,487,000 | $-20,291,000 | $-39,208,000 | $-67,636,000 | $-30,280,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-104.35 | $-4711.54 | $-56011.00 | $-122924.00 | $-93616.00 |
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Visit WebsiteEarnings History & Surprises
WINTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 19, 2025 | — | $-1.08 | — | — |
Q3 2025 | Aug 19, 2025 | $-99.00 | $-3.06 | +96.9% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-180.00 | $-4.63 | +97.4% | ✓ BEAT |
Q2 2025 | Apr 15, 2025 | $-23.32 | $-99.99 | -328.8% | ✗ MISS |
Q4 2024 | Nov 26, 2024 | $-2.27 | $-211.50 | -9217.2% | ✗ MISS |
Q3 2024 | Aug 19, 2024 | $-405.50 | $-1045.50 | -157.8% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-495.00 | $-462.50 | +6.6% | ✓ BEAT |
Q2 2024 | Apr 16, 2024 | $-0.94 | $-665.47 | -70694.7% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.63 | $-773.38 | -122658.7% | ✗ MISS |
Q3 2023 | Aug 7, 2023 | $-0.68 | $-1474.82 | -216785.3% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.56 | $-4280.58 | -764289.3% | ✗ MISS |
Q2 2023 | Apr 3, 2023 | $-9450.00 | $-11699.64 | -23.8% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-13489.21 | $-5845.32 | +56.7% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-4946.04 | $-8543.17 | -72.7% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-13938.85 | $-13039.57 | +6.5% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $-14838.13 | $-20683.46 | -39.4% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-13489.21 | $-13938.85 | -3.3% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-23381.29 | $-63848.92 | -173.1% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-15.00 | $-22931.65 | -152777.7% | ✗ MISS |
Frequently Asked Questions about WINT
What is WINT's current stock price?
What is the analyst price target for WINT?
What sector is Windtree Therapeutics, Inc. in?
What is WINT's market cap?
Does WINT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to WINT for comparison